Full-Time

R&D Clinical and Medical Coding Analyst

Multiple Teams

Posted on 9/30/2025

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$106.3k - $130k/yr

+ Variable Incentive Pay

No H1B Sponsorship

Colorado, USA

Remote

New employees will be required to travel to a designated company location for on-site onboarding during their initial days of employment.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s Degree AND 5 years’ experience in the healthcare industry in one or more of the following: outpatient medical coding and billing operations, outpatient prior authorization or denials management, outpatient healthcare claims and processing optimization, payor claims design and edit management, and outpatient healthcare services research and analytics.
  • Significant experience working with excel, databases, and ability to learn computer applications for analysis.
  • Comfortable in a multicultural, complex, cross-functional, and dynamic work environment, able to prioritize, multi-task, focus on goals, take accountability, and manage time well.
  • Ability to take individual initiative and responsibility for assignments while working independently and in a team environment.
  • Must demonstrate the ability to collaborate effectively with cross-functional teams—including clinicians, researchers, and engineers—to communicate and train on clinical workflows, healthcare coding systems, and patient classification methodologies, while providing enthusiastic leadership that drives team engagement and performance.
Responsibilities
  • Providing subject matter expertise in the clinical content development, specification, documentation, validation, application, and maintenance of the Solventum outpatient public and proprietary groupers, code editors, and software including Tricare, Home Health, IOCE (Integrated Outpatient Code Editor), and EAPG (Enhanced Ambulatory Payment Grouper).
  • Contributing and coordinating with the research efforts related to the methodologies, provide input into the prioritization of the potential research enhancements.
  • Work directly with the Chief Product Owner, Product Owners, and Research team to drive enhancements to the methodologies by translating the clinical hypotheses into clinical logic content specifications using existing coding systems; documenting and maintaining clear clinical specifications.
  • Work directly and collaborate with the technical, quality, and clinical team members, integrating product concepts to implement and evaluate the clinical specification.
  • Responsible for maintaining process documentation for the methodologies update using C&ER standards and methods.
Desired Qualifications
  • Master's degree in health field, clinical informatics, clinical coding, and/or HIM credentials.
  • Familiarity with patient classification research and development: Outpatient coding and payment systems, Commercial, Medicare and Medicaid environments, Risk adjustment.
  • Deep Knowledge of ICD-10-CM, CPT, NDC, and APC, with additional knowledge of ICD-10-PCS, HCPCS, APC, HCC, and DRG.
  • Ability to evaluate research questions, analyze results and statistical output and patterns, and document hypotheses and recommendations.
  • Healthcare software product development experience, bringing products from initial concept to release.
  • Healthcare payer, delivery or industry experience in healthcare quality, population health, care management.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Advanced wound care and Acera Surgical deepen Solventum’s synthetic tissue position.
  • Eagan Innovation Hub accelerates R&D in wound care, sterilization, and digital health.
  • Purification sale and 2026 buyback improve capital focus and shareholder returns.

What critics are saying

  • AI-native documentation vendors threaten the Health Information Systems revenue base.
  • ERP rollout disruptions are already distorting orders across infection prevention, surgical, and dental.
  • Dependence on volume growth leaves Solventum exposed to hospital and dental demand slowdowns.

What makes Solventum unique

  • Spin-off from 3M in April 2024 gave Solventum a focused healthcare portfolio.
  • Bryan Hanson leads four segments: MedSurg, Dental, Health Information Systems, Purification.
  • Over 7,300 patents support decades of healthcare materials and workflow innovation.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Solventum who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

0%
Simply Wall St
Apr 5th, 2026
Solventum opens $200M Innovation Hub as CAO prepares to retire

Solventum Corporation has opened a $200 million Innovation Hub in Eagan, Minnesota, housing over 1,800 employees and supported by approximately $13 million in state business development funding. The facility focuses on research and development in healthcare innovation, particularly advanced wound care, sterilisation and digital health. The opening coincides with Chief Accounting Officer Mary Wilcox announcing her retirement, effective once a successor is appointed. Wilcox informed the company of her intention on 20 March 2026. The Innovation Hub supports Solventum's emphasis on new product development following its separation from 3M. However, analysts note that near-term execution risks around ERP implementation and supply chain transition remain key factors for investors to monitor.

Yahoo Finance
Mar 1st, 2026
Solventum sells Purification unit, buys Acera Surgical, launches $1B buyback in first year post-3M spin

Solventum reported fourth-quarter sales of $2.0 billion, with organic growth of 3.5% year-over-year, though reported revenue declined 3.7% due to its Purification & Filtration divestiture and the Acera acquisition. Non-GAAP earnings per share reached $1.57, whilst adjusted operating margin was 19.9%. Gross margin fell 230 basis points to 53.5%, with roughly 150 basis points attributed to one-time separation costs from 3M. For 2026, the company guided organic sales growth of 2%–3%, operating margin of 21%–21.5%, and EPS of $6.40–$6.60. Management expects free cash flow around $200 million, or roughly $1 billion excluding separation and divestiture costs. The company closed its acquisition of Acera Surgical to enter the synthetic tissue market and launched a $1 billion share buyback programme. Solventum aims to exit approximately 90% of transitional service agreements with 3M by year-end 2026.

Yahoo Finance
Feb 26th, 2026
Solventum beats quarterly estimates as surgical product demand drives $2B revenue

Solventum, a Minnesota-based medical device maker, beat Wall Street estimates for the fourth quarter, driven by strong demand for wound care and sterilisation products. Revenue reached $2 billion, surpassing analysts' expectations of $1.96 billion, whilst adjusted earnings per share came in at $1.57 versus estimates of $1.50. The company's MedSurg business, which accounts for over half of total revenue, saw sales rise 5.2% year-on-year to $1.24 billion. Solventum forecast 2026 adjusted profit of $6.40 to $6.60 per share, above Wall Street expectations of $6.34. The company is acquiring Acera Surgical for up to $850 million to expand its wound care portfolio and has launched a four-year programme expected to deliver $500 million in annual savings.

Yahoo Finance
Feb 26th, 2026
Solventum Q4 earnings beat expectations with $2B revenue, projects $6.40-$6.60 per share for 2025

Solventum reported fourth-quarter net income of $63 million, or $1.57 per share on an adjusted basis, exceeding Wall Street expectations of $1.50 per share. The Maplewood, Minnesota-based healthcare company posted revenue of $2 billion, surpassing analyst forecasts of $1.97 billion. For the full year, Solventum reported profit of $1.56 billion, or $8.88 per share, with revenue of $8.32 billion. The company expects full-year earnings between $6.40 and $6.60 per share.

PR Newswire
Feb 26th, 2026
Solventum reports Q4 2025 results with 3.5% organic sales growth, sets 2026 guidance

Solventum reported fourth quarter 2025 results with sales of $2 billion, down 3.7% on a reported basis but up 3.5% organically. GAAP diluted earnings per share were $0.36, whilst adjusted diluted earnings per share reached $1.57. Operating cash flow totalled $96 million, with free cash flow of $33 million. The healthcare company's organic sales growth was driven by its Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions. Full-year 2025 results exceeded expectations for both sales and earnings per share. For 2026, Solventum projects organic sales growth of 2.0% to 3.0%, adjusted earnings per share of $6.40 to $6.60, and free cash flow of approximately $200 million. The company, which spun off from 3M, continues its transformation journey.

INACTIVE